Curing 'diabetic nephropathy' is considered an unmet medical need of high priority. We propose to question the concept of 'diabetic nephropathy' that implies diabetes as the predominant cause of kidney disease, which may not apply to the majority of type 2 diabetics approaching end-stage kidney disease. With the onset of diabetes, hyperglycaemia/sodium-glucose cotransporter-2-driven glomerular hyperfiltration promotes nephron hypertrophy, which, however, on its own, causes proteinuria not before a decade later, probably because podocyte hypertrophy can usually accommodate an increase in the filtration surface. In contrast, precedent chronic kidney disease (CKD), that is, few nephrons per body mass, e.g. due to poor nephron endowment from birth, obesity, pregnancy, or renal ageing or injury-related nephron loss, usually precedes the onset of type 2 diabetes. This applies in particular in older adults, and each on its own, but especially in combination, further aggravates single nephron hyperfiltration and glomerular hypertrophy. Whenever this additional hyperglycaemia-driven enlargement of the glomerular filtration surface exceeds the capacity of podocytes for hypertrophy, podocytes detachment leads to glomerulosclerosis and nephron loss, i.e. CKD progression. Animal models of 'diabetic nephropathy' based only on hyperglycaemia do not mimic this aspect and therefore poorly predict outcomes of clinical trials usually performed on elderly CKD patients with type 2 diabetes. Thus, we advocate the use of renal mass (nephron) ablation in type 2 diabetic animals to better mimic the pathophysiology of 'CKD with diabetes' in the target patient population and the use of the glomerular filtration rate as a primary endpoint to more reliably predict trial outcomes.
A B S T R A C T
Curing 'diabetic nephropathy' is considered an unmet medical need of high priority. We propose to question the concept of 'diabetic nephropathy' that implies diabetes as the predominant cause of kidney disease, which may not apply to the majority of type 2 diabetics approaching end-stage kidney disease. With the onset of diabetes, hyperglycaemia/sodium-glucose cotransporter-2-driven glomerular hyperfiltration promotes nephron hypertrophy, which, however, on its own, causes proteinuria not before a decade later, probably because podocyte hypertrophy can usually accommodate an increase in the filtration surface. In contrast, precedent chronic kidney disease (CKD), that is, few nephrons per body mass, e.g. due to poor nephron endowment from birth, obesity, pregnancy, or renal ageing or injury-related nephron loss, usually precedes the onset of type 2 diabetes. This applies in particular in older adults, and each on its own, but especially in combination, further aggravates single nephron hyperfiltration and glomerular hypertrophy. Whenever this additional hyperglycaemia-driven enlargement of the glomerular filtration surface exceeds the capacity of podocytes for hypertrophy, podocytes detachment leads to glomerulosclerosis and nephron loss, i.e. CKD progression. Animal models of 'diabetic nephropathy' based only on hyperglycaemia do not mimic this aspect and therefore poorly predict outcomes of clinical trials usually performed on elderly CKD patients with type 2 diabetes. Thus, we advocate the use of renal mass (nephron) ablation in type 2 diabetic animals to better mimic the pathophysiology of 'CKD with diabetes' in the target patient population and the use of the glomerular filtration rate as a primary endpoint to more reliably predict trial outcomes.
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I N T R O D U C T I O N
'Diabetic nephropathy' is considered a highly prevalent disease entity, accounting for the majority of patients with end-stage kidney disease (ESKD) in most parts of the world. Hence, finding cures for 'diabetic nephropathy' represents a global unmet medical need of high priority. As a consequence, considerable public and industrial financial resources have been allocated to tackle 'diabetic nephropathy'. Large cohort studies have collected biosamples from patients with 'diabetic nephropathy' to identify molecular targets using the latest omics platforms [1, 2] . Molecular biologists approach the problem by studying all types of kidney cells under high glucose conditions, resulting in a extended list of presumed pathomechanisms of unknown hierarchical importance but anyway considered to represent a valuable molecular target for treatment. In vivo validation usually implies inducing diabetes in rats and mice and demonstrating that inhibitors of such pathways attenuate kidney injury, findings that raise hopes that clinical trials may reproduce these protective outcomes. However, if conducted, such clinical trials often do not meet their primary endpoint, leading to disappointed patients, physicians, basic scientists, industry partners and their stakeholders (Table 1) .
There are many possible explanations for the low yield of translational research in 'diabetic nephropathy'. In this review, we focus on the value of animal models in predicting clinical trial outcomes, an Achilles heel in drug development programmes. The paucity of reliable animal models of 'diabetic nephropathy' is a common concern among industry partners in considering whether or not to invest millions into a clinical trial. Others have addressed this issue by searching for models that best mimic nodular glomerulosclerosis [52] , an lesion described in 1936 by Kimmelstiel and Wilson [53] in patients with and without diabetes. Here we propose that addressing the disease entity of 'diabetic nephropathy' itself represents a conceptual hurdle for solving a clinical problem of utmost relevance-the prevention of ESKD in patients with diabetes. The terms 'diabetic nephropathy' and its updated version 'diabetic kidney disease' both imply a causative role of diabetes in kidney disease. We do not question that 'diabetic nephropathy' exists. It occurs in (young) patients with normal nephron numbers per body mass not before a decade after the onset of diabetes [54] . Rigorous diabetes control can prevent, halt or even revert kidney disease [55] [56] [57] . However, the vast majority of diabetes-related ESKD patients are older adults with metabolic syndrome, which often implies ageing-and injury-related chronic kidney disease (CKD) as comorbidities preceding the onset of diabetes [58] [59] [60] [61] -a circumstance clearly affecting the renal prognosis and not adequately being represented by the term 'diabetic nephropathy'. Indeed, kidney biopsy studies have documented a wide variety of underlying non-diabetic kidney injuries in patients with suspected 'diabetic nephropathy' [62] .
We therefore propose to add to the terms 'diabetic nephropathy' and 'diabetic kidney disease' the term 'CKD with diabetes' (CKD þ D) when referring to the clinical problem of diabetes-related progression of CKD to ESKD. Using the term 'CKD þ D' allows resetting our conceptual approach on how to solve the clinical problem of CKD progression to ESKD in diabetes. In this article, we start by reviewing the pathophysiology of 'diabetic nephropathy' versus 'CKD þ D' in order to deduce practical implications on how to design meaningful pre-clinical animal studies that better predict clinical trial outcomes.
T H E P A T H O P H Y S I O L O G Y O F ' D I A B E T I C N E P H R O P A T H Y ' V E R S U S ' C K D W I T H D I A B E T E S '

Low nephron number per body mass drives nephron hyperfiltration and hypertrophy
Although hyperglycaemia is the same in type 1 and type 2 diabetes, progressive CKD develops much faster in patients with type 2 diabetes, compared with those with type 1 diabetes [63] . To understand this difference, we must consider renal function as the product of the number of nephrons multiplied by the single nephron glomerular filtration rate (SNGFR). The nephron number is set at birth and declines with age as a consequence of: (i) ageing-related podocyte loss and subsequent glomerulosclerosis (ageing nephropathy) [64] and (ii) episodes of acute kidney injury or non-diabetic forms of CKD ( Figure 1A ). The nephron number is not the same for everyone and the bellshaped curve for the glomerular filtration rate (GFR) across the population probably illustrates a similar distribution for nephron numbers ( Figure 1A ). When the nephron number is too low for the body mass, remnant nephrons get exposed to a higher filtration load, which increases the SNGFR, a trigger for remnant nephron hypertrophy ( Figure 1B) . Indeed, biopsy studies have described an inverse relationship between lower nephron numbers and increasing sizes of glomerular and tubular cross-sections [64, 65] . Increasing the size of the glomerulus (and the entire nephron) is a compensatory response to solve When diabetes affects a (young or old) person with a sufficient number of nephrons per body mass, hyperglycaemia/SGLT2-driven single nephron hyperfiltration will increase the total GFR and lead to mild hypertrophy of all nephrons. Significant CKD develops only after many years of delay, i.e. 'diabetic nephropathy' or 'diabetic kidney disease' (¼ kidney disease induced by diabetes). In contrast, people with low nephron number per body mass (due to low nephron endowment, nephron loss, obesity or pregnancy) already experience various degrees of remnant nephron hyperfiltration and hypertrophy before the onset of diabetes. With the onset of diabetes, hyperglycaemia/SGLT2-driven hyperfiltration drives further nephron hypertrophy more rapidly promoting proteinuria, podocyte loss, glomerulosclerosis and nephron loss, i.e. progression of CKD to ESKD. (C) The three-dimensional graph illustrates the additive effects of combinations of low nephron number per body mass, ageing-and injury-related nephron loss or hyperglycaemia to drive glomerular hypertrophy. Glomerular hypertrophy can reduce hyperfiltration-related filtration pressure by increasing the filtration surface. While mesangial cells and endothelial cells can increase in number, the post-mitotic podocytes can accommodate an increase in the glomerular filtration surface only by hypertrophy and stretching up to a certain threshold. Beyond that, threshold podocytes detach from the glomerular basement membrane and get lost in the urine. The consequence is focal, and subsequently global, glomerulosclerosis followed by loss of the respective nephron that is degraded and replaced by interstitial matrix. Nephron loss further increases the filtration load on the remnant nephrons, a process accelerating CKD progression. These pathomechanisms are poorly represented in most animal models of 'diabetic nephropathy'. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; FSGS, focal segmental glomerulosclerosis; GFR, glomerular filtration rate; SGLT2; sodiumglusoce (co-)transporter-2.
two problems: (i) it reduces glomerular hypertension by increasing the filtration surface [66] and (ii) by increasing the SNGFR, it softens the corresponding decline in the total GFR. This implies that the total GFR, a parameter very much used in clinical practice, notoriously underestimates poor nephron endowment or irreversible losses of renal mass [67] . Indeed, many adults with an apparently normal renal function have already consumed their renal reserve for permanent hyperfiltration of hypertrophic remnant nephrons. For example, kidney donors seem apparently healthy with 'normal' renal function, despite lacking 50% of nephrons, substantial remnant nephron hypertrophy and increased SNGFR. To conclude, the vast majority of adult patients with type 2 diabetes experience the onset of hyperglycaemia with a much lower number of nephrons, compared with children or adolescents, and remnant nephron hyperfiltration and hypertrophy, presenting with either a 'normal' total GFR or an unspectacular GFR impairment, such as CKD2. Therefore, we prefer to use the term 'CKD þ D' to clarify the difference as to what 'diabetic nephropathy' is. In vitro studies with cells cultured under high glucose conditions or animal models based on the induction of diabetes in young mice devoid of precedent nephron hyperfiltration and hypertrophy cannot mimic the structural and haemodynamic alterations present in adult or elderly patients with diabetes. A low nephron number per body mass is also present in those with low nephron endowment from birth, with its extreme form in kidney hypoplasia, in obesity commonly present in patients with type 2 diabetes, and transiently during pregnancy ( Figure 1C) . In all these conditions, nephrons face single nephron hyperfiltration driving hypertrophy to reduce the filtration pressure [68] . Obviously, any combination of these factors aggravates remnant nephron hyperfiltration and hypertrophy preceding the onset of diabetes ( Figure 1C ).
Hyperglycaemia/SGLT2-related hyperfiltration promotes nephron hypertrophy
Diabetic kidney disease profoundly differs from nondiabetic kidney disease in many ways, e.g. by an increased GFR in its early phases and by its partial responsiveness to reninangiotensin system inhibition [69] . These two phenomena can be explained by renal physiology, and not by molecular biology, inflammation, fibrosis or omics research [70] . Hyperglycaemia drastically increases the glucose concentration in the glomerular ultrafiltrate in the proximal tubule, which induces the expression of the sodium-glucose co-transporter (SGLT)-2 in the S2 segment of the proximal tubule [71] . Enhanced reabsorption of glucose, together with sodium, in the proximal tubule (renal gluconeogenesis) reduces exposure of sodium chloride to the macula densa, a process that deactivates the tubuloglomerular feedback (TGF) mechanism and persistently dilates all afferent glomerular arterioles and induces renin secretion [70, 72] . Thus, hyperglycaemia indirectly increases the SNGFR, which implies glomerular hypertension, unless subsequently enlarging glomerular dimensions reduce pressure by increasing the filtration surface ( Figure 1C ). Hyperglycaemia/SGLT2-induced single nephron hyperfiltration accounts for the elevated total GFR in (young) patients with normal nephron numbers and display their renal reserve up to the maximal GFR [54] . The same occurs in (older) patients with low nephron numbers, but with their maximized SNGFR no longer presenting as an increased total GFR, but rather as a normal or mildly decreased total GFR [73] . Thus, in type 2 diabetes) the total GFR often masks the underlying CKD and the risk for CKD progression as determined by the nephron number.
Hyperglycaemia/SGLT2-induced hyperfiltration in particular threatens patients with precedent low nephron numbers Hyperfiltration-induced enlargement of the filtration surface challenges podocytes to maintain the filtration barrier, but as the podocyte is a post-mitotic cell that cannot divide, this can only be achieved via podocyte hypertrophy [74, 75] . In (young) patients with normal nephron numbers, podocyte hypertrophy can easily and sufficiently accommodate an increase in the filtration surface-that is why it takes a decade to develop 'diabetic nephropathy' ( Figure 1C ) [54] . In contrast, when hyperglycaemia/SGLT2-induced glomerular hyperfiltration adds on to precedent hyperfiltration secondary to several causes of low nephron numbers per body mass, further nephron hypertrophy implies further podocyte shear stress ( Figure 1C ) [76] . At some point, podocyte hypertrophy reaches its limits and podocytes can no longer accommodate further increases in the filtration surface and the associated shear stress ( Figure 1C ) [77] . This results in barrier dysfunction and podocyte detachment (as evident by proteinuria), followed by glomerulosclerosis and nephron loss (as evident by progressive GFR decline) ( Figure 1C ) [74, 75] . The additive effect of hyperglycaemia/ SGLT2-induced single nephron hyperfiltration, obesity and remnant nephron hyperfiltration not only explains the different temporal dynamics of kidney disease in young and older patients with diabetes, but also the heterogeneity in renal manifestations among patients of all ages, which, at least in part, will also be related to the bell-shaped curve of nephron endowment across the population. This concept implies that normalizing glucose control and reducing single nephron hyperfiltration are the primary therapeutic targets in preventing the progression of 'CKD þ D'.
The hierarchy of pathomechanisms
The pathophysiology of kidney disease in diabetes definitely includes many other factors such as accumulation of advanced glycation end products, endothelial dysfunction, secondary metabolic and inflammatory pathways, as well as tissue remodelling and fibrosis [78] . Identifying the hierarchical significance of the growing list of mechanisms is mandatory to stratify resources for research and clinical trial programmes and to successfully generate new treatment options for clinical practice (Figure 2A) .
Undoubtedly, controlling hyperglycaemia is a central strategy to attenuate hyperglycaemia-related kidney injury. However, too tight glucose control involves hypoglycaemia-related morbidity and mortality [79, 80] . As a consequence, nowadays diabetes control tolerates some degree of persistent hyperglycaemia, implying considerable persistent single nephron hyperfiltration and hypertrophy in the majority of older patients with type 2 diabetes [69, 81] .
The robust effect of dual SGLT2/RAS inhibition on longterm outcomes of 'CKD þ D' clearly highlights the central importance of glomerular hyperfiltration, implying that GFR reduction, rather than increasing the GFR, is the main therapeutic goal to prevent podocyte and nephron loss [51] ( Figure 2B ).
Although hyperglycaemia-induced production of reactive oxygen species and other metabolic changes in renal cells, intrarenal inflammation and interstitial fibrosis seem obvious therapeutic targets, based on descriptive studies comparing healthy kidneys with those in 'diabetic nephropathy', clinical trial evidence is still lacking on whether targeting inflammation and fibrosis can significantly prevent nephron loss and ESKD beyond correcting single nephron hyperfiltration.
Thus, hyperglycaemia/SGLT2-driven glomerular hyperfiltration presents as a central upstream pathomechanism of kidney injury in diabetes (Figure 2A) . Patients with strong nephron endowment can compensate for diabetes-related hyperfiltration quite well for even up to a decade. In contrast, in those with a low number of hyperfiltrating and hypertrophic nephrons, this exceeds the compensatory capacity much earlier. Excessive podocyte shear stress and over-stretching is ultimately followed by detachment of more and more podocytes, proteinuria, secondary focal segmental glomerulosclerosis (FSGS), nephron loss and interstitial fibrosis [69] . To date, the protective potential of the upstream pathomechanism of glomerular hyperfiltration with SGLT2 and RAS inhibition has been well described in clinical trials, whereas evidence of similar effect size in targeting more downstream pathomechanisms is not available.
A N U N M E T M E D I C A L N E E D I N ' C K D W I T H D I A B E T E S ' -A M A R K E R O F N E P H R O N N U M B E R
This field suffers from the lack of a clinically relevant biomarker that reliably allows assessment of single nephron hyperfiltration and predicts CKD progression to ESKD. Proteinuria, doubling of serum creatinine and estimated GFR (slope) all have their weaknesses in predicting CKD progression over a considerably short period of time. Many of these problems could be overcome with a clinically useful marker of nephron number. Being able to repetitively quantify the nephron number would allow: (i) the identification of patients at risk for CKD among those with diabetes at all ages; (ii) the identification of patients with precedent CKD unrelated to diabetes via an obvious discrepancy between the nephron number and the duration of diabetes; (iii) the calculation of the SNGFR (¼ total GFR/nephron number), which would allow the determination of single nephron hyperfiltration, even in patients with an apparently 'normal' GFR; (iv) the monitoring of the SNGFR during therapy to determine the in vivo efficacy of drugs with a view to modulating hyperfiltration and predicting long-term nephroprotective effects; (v) use of the marker of nephron number as an endpoint parameter in clinical trials; and (vi) the prediction of ESKD, e.g. by quantifying the slope of nephron loss. Currently, such a marker is not available, but defining it as a major unmet . Precedent low nephron number per body mass already implies precedent single nephron hyperfiltration and hypertrophy. With the onset of type 2 diabetes, hyperglycaemia/SGLT2-driven glomerular hyperfiltration adds on to that and drives additional nephron hypertrophy to reduce the filtration pressure. Nephron hypertrophy exceeding the capacity of podocytes to accommodate the increasing filtration surface by podocyte hypertrophy leads to podocyte detachment and loss. Podocyte loss results in macroproteinuria and secondary focal segmental glomerulosclerosis, progressing to global glomerulosclerosis and nephron loss. Interstitial fibrous tissue replaces lost nephrons to stabilize the remnant nephrons that need to undergo hypertrophy to meet the filtration load. (B) The upstream importance of glomerular hyperfiltration as a central pathomechanism of 'CKD þ D' is highlighted by the profound renoprotective effect of dual inhibition with SGLT2 and RAS inhibitors (RASi, SGLT2i), e.g. in the EMPA-REG outcome trial. Only GFR reduction with dual RAS/SGLT2 blockade to a submaximal GFR leads to long-term stabilization of the GFR. CKD, chronic kidney disease; CKD þ D, chronic kidney disease plus diabetes; FSGS, focal glomerulosclerosis; GFR, glomerular filtration rate; HG, hyperglycaemia; RASi, renin-angiotensin system inhibitor; SGLT2, sodium-glucose (co-)transporter-2. 
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Type 2 diabetes þ renal mass reduction , mice with leptin deficiency on a black and tan brachyuric strain (BTBR) that is naturally insulin-resistant; db/db, mice with a mutation in the gene encoding the leptin receptor; eNOS -/-, mice with functional deficiency of endothelial nitric oxide synthase; GFR, glomerular filtration rate; HFD, high-fat diet; KO, knockout; MKR, mice with functional inactivation of insulin-like growth factor-1 receptor in the skeletal muscle; NOD, non-obese diabetic; ob/ob, mice with spontaneous recessive point mutation in the gene encoding leptin; STZ, streptozotocin; Tg, transgenic; UNx, uninephrectomy.
medical need may launch more research efforts to eventually solve this problem.
A N I M A L M O D E L S O F ' D I A B E T I C N E P H R O P A T H Y ' V E R S U S P R O G R E S S I
The gap between the design of pre-clinical studies ('trials') using animal models of 'diabetic nephropathy' and the design of clinical trials, and in particular including their preferred high-risk target populations, is one of the hurdles in translational research and drug development programmes (Table 2) . A typical pre-clinical study is conducted in young and lean C57BL/6 mice upon diabetes induction with streptozotocin or in nonobese diabetic (NOD) or Akita mice, all mimicking type 1 diabetes in adolescents, and not the target populations recruited into clinical trials [82] [83] [84] . These models mimic only hyperglycaemia/SGLT2-related glomerular hyperfiltration and therefore generate nothing more than early kidney abnormalities such as some degree of albuminuria, but they usually fail to mimic progressive CKD. To test for progressive CKD would require GFR measurements as the clinically most relevant endpoint parameter, but this is not yet broadly established [52] . It is of note that the endothelial nitric oxide synthase knockout db/db mouse displays spontaneous GFR decline at 6.5 months of age [96] . Some of the spontaneous models of type 2 diabetes such as ob/ ob, db/db or Agouti, among others, also present with obesity, which adds the component of low nephron number per body mass as a second driver of glomerular hyperfiltration and hypertrophy, but significant proteinuria and glomerulosclerosis still need months to develop [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] (Table 2) . Obese type 2 diabetic mice represent a suitable model of adolescent patients with type 2 diabetes, but such patients usually participate in clinical trials only in low numbers, if at all [96] . To better mimic the average 60-year-old participant of a clinical trial, studies with older mice would be necessary, but this is hardly feasible for economic reasons. Surgical renal mass ablation is an option to experimentally mimic the consequences of ageing-or injuryrelated nephron loss, i.e. remnant nephron hyperfiltration and hypertrophy, and to accelerate the onset of the downstream consequences, i.e. podocyte loss, glomerulosclerosis, nephron loss and interstitial fibrosis, just like in patients affected by 'CKD þ D' [97] (Table 2) . Uninephrectomy has been largely used for this purpose [92, [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] . Surgical renal mass reduction up to 5/6 nephrectomy has also been widely used to induce CKD. Following 5/6 nephrectomy, even non-diabetic mice develop proteinuria as a consequence of remnant nephron hyperfiltration, glomerular hypertension and nephron hypertrophy [105] (Table 2) . Surgical renal mass ablation mimics normal or reduced total GFR, despite significant single nephron hyperfiltration [93, 94] , an experimental option to reduce the gap between pre-clinical animal models and clinical trial participants (Tables 1 and 2 ). Indeed, pre-clinical studies performed in uninephrectomized db/db mice reliably predicted the outcomes of several Phase 2 clinical trials, for example, studies with antagonists of the pro-inflammatory chemokine CCL2/MCP1 (chemokine ligand CCL2 monocyte chemoattractant protein) [98, 106] or its corresponding CC-chemokine receptor CCR2 [102, 107] . It is of note that beyond proteinuria, assessing the total GFR in pre-clinical animal studies is essential because GFR is a major determinant of the primary endpoints used in clinical trials and relevant for drug approval. Conversely, a study not demonstrating the effects on the GFR is of little use in terms of predicting trial outcomes. Finally, histomorphological readouts may support mechanistic clues but lack predictive relevance as histology is not available as an endpoint in clinical trials.
It is also of note that vascular lesions, which are a hallmark of human 'diabetic nephropathy', do not occur to the same extent in any of the animal models. It is likely that vascular lesions play an important role in the development of glomerular lesions and the progression of CKD to ESKD. This implies that even optimized animal models of 'CKD þ D' may fall short in accurately predicting the human scenario. Therefore, what we propose here can only initiate a change in how to address the clinical problem experimentally, but obviously further refinements are needed.
C O N C L U S I O N S
The low yield of translational research has led us to reconsider the disease concept and drug development strategies of kidney disease in diabetes. The pandemic of obesity and diabetes largely refers to older adults with type 2 diabetes where diabetes often rather accelerates precedent remnant nephron hyperfiltration and hypertrophy, a state we refer to as 'CKD þ D'. Therefore, finding cures for 'diabetic nephropathy' or 'diabetic kidney disease' may not necessarily produce interventions that are of use in 'CKD þ D'. This issue may explain why many clinical trials did not reproduce the findings generated in mice or rats with 'diabetic nephropathy'. Our updated disease concept of 'CKD þ D' has four important implications: (i) reducing SNGFR with dual blockade of SGLT2 and RAS inhibitors to submaximal levels should be considered as the central management paradigm, which implies a substantial reduction of the total GFR in patients (filtration load reduction to preserve remnant nephrons); (ii) the design of pre-clinical animal studies should include renal mass reduction to mimic remnant nephron hyperfiltration and hypertrophy before diabetes induction; (iii) novel therapies should be tested in animals, in addition to a new standard of care, i.e. dual SGLT2/RAS inhibition and moderate diabetes control, to better predict clinical trial outcomes for which the new standard of care will be mandatory; and (iv) for the same reason, animal studies should use the same endpoint parameters as clinical trials to assess efficacy, i.e. GFR and renal death. These conceptual and practical modifications may help to more efficiently target the remaining unmet medical need related to renal manifestations of the obesity and diabetes pandemic.
G L O S S A R Y
CKD with diabetes: term used to describe diabetes as a comorbidity to CKD without implying whether or not diabetes itself caused it. Using this term may help to overcome a number of conceptual and practical hurdles in the domain of 'diabetic nephropathy'.
Diabetic kidney disease: term used to less specifically describe kidney abnormalities in patients with diabetes, but the term still implies a causal role of diabetes in kidney disease. However, this remains often uncertain, especially in patients with type 2 diabetes. Dissecting diabetic from non-diabetic forms of CKD may correct not only the current view on the epidemiology of kidney disease, but also the conceptual approach to drug development, translational research and patient management.
Diabetic nephropathy: term used to describe renal manifestations in patients with diabetes. The term implies a causal role of diabetes in kidney disease, although this remains often uncertain, especially in patients with type 2 diabetes. Dissecting diabetic from non-diabetic forms of CKD may correct not only the current view on the epidemiology of kidney disease, but also the conceptual approach to drug development, translational research and patient management. Glomerular hyperfiltration: increased SNGFR either due to impaired autoregulation of glomerular haemodynamics or as a consequence of a reduced nephron number/body mass ratio, as it occurs in low nephron endowment from birth, in obesity or following nephron loss. Glomerular hyperfiltration implies glomerular hypertension, unless glomerular hypertrophy reduces pressure by increasing glomerular diameters and the filtration surface. Glomerular hypertension: increased pressure gradient across the glomerular filtration barrier, e.g. whenever glomerular hyperfiltration is not associated with a corresponding increase in glomerular dimensions (hypertrophy), which would normalize pressure. Kidney hypertrophy: a kidney made of hypertrophic nephrons, not equal to increased kidney size that could have other reasons such as kidney lymphoma or amyloidosis. Nephron hypertrophy: increased dimensions of nephrons, usually as a consequence of hyperfiltration, rarely of growth hormone excess. Hypertrophy affects the diameters of Bowman's capsule and the tubule, including increased length of glomerular capillaries and of convoluted tubules. Hypertrophy also occurs in post-mitotic renal cells, i.e. podocytes and tubular epithelial cells. Hyperfiltration-driven glomerular hypertrophy exceeding the capacity of podocyte hypertrophy leads to podocyte stretching and detachment, which becomes clinically evident by proteinuria.
Nephron number: critical parameter for kidney function as nephron number Â SNGFR ¼ total GFR. Unfortunately, currently a clinically applicable marker of the nephron number is not yet available. Currently used biomarkers of CKD underestimate the underlying irreversible parenchymal loss, trivializing the long-term prognosis. Renal reserve: functional filtration reserve beyond the submaximal GFR physiologically present in unchallenged conditions. Consuming renal reserve implies single nephron hyperfiltration. Renal reserve can be determined by measuring the GFR before and after a load of amino acids. Renal reserve is transiently recruited after food and fluid intake and during pregnancy. Renal reserve is permanently recruited (implying persistent single nephron hyperfiltration) after nephron loss/donation, obesity and diabetes. In contrast to nephron loss/donation and obesity, diabetes increases the SNGFR by deactivating the TGF, leading to persistent dilation of afferent glomerular arterioles.
SGLT2: sodium-glucose (co-)transporter-2. SGLT2 is expressed in the S2 segment of the (convoluted) proximal tubule to reabsorb the freely filtered glucose (renal gluconeogenesis). In diabetes, hyperglycaemia massively increases glucose exposure to the proximal tubule, which: (i) induces SGLT2 and (ii) massively increases proximal glucose reabsorption, the latter leading to deactivation of the TGF (consequences seen there). Total GFR: SNGFR multiplied by the number of nephrons represents the total GFR. In diabetes, the total GFR should be considered to be close to the maximal GFR, as hyperglycaemia/ SGLT2-driven hyperfiltration consumes the renal reserve. However, this implies a persistent volume (and pressure) load across the filtration barrier underlying 'diabetic nephropathy', especially in patients with low nephron number. Tubulo-glomerular feedback (TGF): autoregulatory mechanism of glomerular perfusion to maintain submaximal SNGFR or to adequately respond to changes in intravascular fluid volume. The TGF is regulated by the macula densa sensing the sodium chloride concentration in the ascending loop of Henle. Hyperglycaemia deactivates the TGF as SGLT2-driven sodium reabsorption in the proximal tubule reduces sodium delivery to the macula densa, followed by vasodilation of the afferent arteriole. The consequence is a persistent increase in SNGFR. SGLT2 inhibitors elicit nephroprotective effects by reversing this process, thereby reactivating the TGF. A decline in the GFR illustrates this mechanism of action in clinical practice. 
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